UK Trial Could Help Pick Best Covid Vaccine Boosters
Initial Results Due In September
Executive Summary
Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.
You may also be interested in...
UK Chooses Pfizer And Moderna For COVID-19 Boosters, But Questions Remain On Unpublished Trial Data
The UK’s choice of the mRNA vaccines as COVID-19 boosters is no surprise – but not releasing the key study data behind the decision is.
To Boost Or Not To Boost? Pfizer, FDA, And The COVID Vaccine Communication Challenge
Pfizer’s bid for third dose appears to get pushback from the US government, but reticence about the booster may reflect PR considerations more than any fundamental concern about the vaccine.
CureVac Still Hopes Variants Could Win Favor For COVID-19 Vaccine
Patients 18-60 had a protection rate of 53%, but there were too few cases among those older than 60 – a crucial subgroup – in HERALD to draw conclusions about the vaccine’s efficacy among older people.